These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18690967)

  • 1. Human-based in vitro experimental systems for the evaluation of human drug safety.
    Li AP
    Curr Drug Saf; 2007 Sep; 2(3):193-9. PubMed ID: 18690967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of human xenobiotic toxicity: scientific concepts and the novel integrated discrete multiple cell co-culture (IdMOC) technology.
    Li AP
    ALTEX; 2008; 25(1):43-9. PubMed ID: 18360727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of the Integrated Discrete Multiple Organ Co-culture (IdMOC) system for the evaluation of multiple organ toxicity.
    Li AP
    Altern Lab Anim; 2009 Sep; 37(4):377-85. PubMed ID: 19807210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: results with model toxicants aflatoxin B1, cyclophosphamide and tamoxifen.
    Li AP; Uzgare A; LaForge YS
    Chem Biol Interact; 2012 Jul; 199(1):1-8. PubMed ID: 22640811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Adverse Drug Properties with Cryopreserved Human Hepatocytes and the Integrated Discrete Multiple Organ Co-culture (IdMOC(TM)) System.
    Li AP
    Toxicol Res; 2015 Jun; 31(2):137-49. PubMed ID: 26191380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scientific concepts and applications of integrated discrete multiple organ co-culture technology.
    Gayathri L; Dhanasekaran D; Akbarsha MA
    J Pharmacol Pharmacother; 2015; 6(2):63-70. PubMed ID: 25969651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model-based assay design to reproduce in vivo patterns of acute drug-induced toxicity.
    Kuepfer L; Clayton O; Thiel C; Cordes H; Nudischer R; Blank LM; Baier V; Heymans S; Caiment F; Roth A; Fluri DA; Kelm JM; Castell J; Selevsek N; Schlapbach R; Keun H; Hynes J; Sarkans U; Gmuender H; Herwig R; Niederer S; Schuchhardt J; Segall M; Kleinjans J
    Arch Toxicol; 2018 Jan; 92(1):553-555. PubMed ID: 28852801
    [No Abstract]   [Full Text] [Related]  

  • 8. A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma breast cancer cells.
    Li AP; Bode C; Sakai Y
    Chem Biol Interact; 2004 Nov; 150(1):129-36. PubMed ID: 15522266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro human hepatocyte-based experimental systems for the evaluation of human drug metabolism, drug-drug interactions, and drug toxicity in drug development.
    Li AP
    Curr Top Med Chem; 2014; 14(11):1325-38. PubMed ID: 24805059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products.
    Cavagnaro J; Silva Lima B
    Eur J Pharmacol; 2015 Jul; 759():51-62. PubMed ID: 25814257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human hepatocytes: isolation, cryopreservation and applications in drug development.
    Li AP
    Chem Biol Interact; 2007 May; 168(1):16-29. PubMed ID: 17270162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Are non-clinical studies predictive of adverse events in humans?].
    Claude N
    Ann Pharm Fr; 2007 Sep; 65(5):292-7. PubMed ID: 17982375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organ-on-a-chip technology and microfluidic whole-body models for pharmacokinetic drug toxicity screening.
    Lee JB; Sung JH
    Biotechnol J; 2013 Nov; 8(11):1258-66. PubMed ID: 24038956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New technologies in drug metabolism and toxicity screening: organ-to-organ interaction.
    Bhushan A; Martucci NJ; Usta OB; Yarmush ML
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):475-7. PubMed ID: 26940609
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of the intestinal toxicity and transport of xenobiotics utilizing precision-cut slices.
    Niu X; de Graaf IA; Groothuis GM
    Xenobiotica; 2013 Jan; 43(1):73-83. PubMed ID: 23106567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro approaches to evaluate ADMET drug properties.
    Li AP
    Curr Top Med Chem; 2004; 4(7):701-6. PubMed ID: 15032683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative juvenile safety testing of new therapeutic candidates: relevance of laboratory animal data to children.
    Anderson T; Khan NK; Tassinari MS; Hurtt ME
    J Toxicol Sci; 2009; 34 Suppl 2():SP209-15. PubMed ID: 19571471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organ-on-a-Chip Technology for Reproducing Multiorgan Physiology.
    Lee SH; Sung JH
    Adv Healthc Mater; 2018 Jan; 7(2):. PubMed ID: 28945001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.